Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study by Jason Westin, Tycel J. Phillips, Amitkumar Mehta, Marc S. Hoffmann, Eva Gonzalez-Barca, Catherine Thieblemont, Mariana Bastos-Oreiro, Richard Greil, Sebastian Giebel, Michael C. Wei, Jue Wang, Reinhard Bucher, Jason Sit, Elicia Penuel, Enkhtsetseg Purev, Donald L. Yee, Juan Miguel Bergua-Burgues

Get full text

DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA by Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos

Get full text